Spotlight on Pulmonary/Respiratory Medicine

Michael G. Ison, MD, MS
Credits: 0.25 CME / MOC / CNE / CPE
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient
Michael G. Ison, MD, MS
RMEI Medical Education, LLC

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Start

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Pulmonary/Respiratory Medicine Presentations

0.25 CME / MOC / IPCE
RMEI Medical Education, LLC
Challenging Cases in Asthma: Optimizing Biologics in Adults

Challenging Cases in Asthma: Optimizing Biologics in Adults

Start

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: August 30, 2022
Expires: August 29, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

You have a middle-aged patient with severe, steroid-dependent asthma, multiple atopic comorbidities, and who has failed biologic after biologic for asthma. What do you do? Listen to what this expert, interprofessional panel recommends for collaborative care team management of this case and others that learners have submitted for their discussion.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 100% on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: August 30, 2022
Expires: August 29, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

You have a middle-aged patient with severe, steroid-dependent asthma, multiple atopic comorbidities, and who has failed biologic after biologic for asthma. What do you do? Listen to what this expert, interprofessional panel recommends for collaborative care team management of this case and others that learners have submitted for their discussion.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 100% on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.25 CME / MOC / IPCE
RMEI Medical Education, LLC
Challenging Cases in Asthma: Improving Quality of Life

Challenging Cases in Asthma: Improving Quality of Life

Start

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: August 30, 2022
Expires: August 29, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

This interprofessional expert panel takes on challenging cases in severe and difficult-to-treat asthma, including pediatrics and non-T2 asthma. In their discussions they weigh different treatment strategies; consider atopic comorbidities; illustrate how asthma affects patients’ quality of life; and how they can work as a team to help optimize patient care from a pulmonology, allergy, and nursing perspective.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 100% on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: August 30, 2022
Expires: August 29, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

This interprofessional expert panel takes on challenging cases in severe and difficult-to-treat asthma, including pediatrics and non-T2 asthma. In their discussions they weigh different treatment strategies; consider atopic comorbidities; illustrate how asthma affects patients’ quality of life; and how they can work as a team to help optimize patient care from a pulmonology, allergy, and nursing perspective.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 100% on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.25 CME / MOC / IPCE
RMEI Medical Education, LLC
Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes in Severe and Difficult-to-Control Asthma

Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes in Severe and Difficult-to-Control Asthma

Start

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: July 25, 2022
Expires: July 24, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

  • Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 80% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: July 25, 2022
Expires: July 24, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

  • Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 80% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Maria E. Arcila, MD
0.75 CME
RMEI Medical Education, LLC
Optimizing Frontline Immunotherapy in Advanced Non-Small Cell Lung Cancer: Program Highlights

Optimizing Frontline Immunotherapy in Advanced Non-Small Cell Lung Cancer: Program Highlights

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: April 8, 2022
Expires: April 7, 2023
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to: 

  • Identify patients with advanced non-small cell lung cancer (NSCLC) eligible for frontline immunotherapy using biomarker test results
  • Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC

Activity Description

This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.

Faculty

Maria E. Arcila, MD
Deputy Chief, Molecular Diagnostics Service
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY


Jared M. Weiss, MD
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, NC



Content Reviewer

Jason M. Chang, MD
Assistant Attending, Molecular and Thoracic Pathology
Memorial Sloan Kettering Cancer Center
New York, NY


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Maria E. Arcila, MD, has relevant financial relationships with AstraZeneca, Bristol-Myers Squibb, Invivoscribe, Janssen Global Services, Merck, Roche (Consultant); Biocartis, Invivoscribe (Speaker/Speaker’s Bureau).

Jason M. Chang, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Jared M. Weiss, MD, has relevant financial relationships with Achilles, En Fuego (convertible note), Lyell, Nuvalent, Vesselon (warrants) (Stock/Shareholder); AbbVie, AstraZeneca, Azitra, Blueprint, Boehringer Ingelheim, Eli Lilly, EMD Serono, G1, Genentech, Genmab, Jazz Pharmaceuticals, Jounce, Nanobiotix, Pfizer, Regeneron, Saatchi, Sumitomo Dainippon Pharma Oncology (Consultant); Amgen, AstraZeneca, Boehringer Ingelheim, G1, Immunicum, Loxo/Lilly, Merck, Mirati, PDS Biotech, Sumitomo Dainippon Pharma Oncology (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 83% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: April 8, 2022
Expires: April 7, 2023
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to: 

  • Identify patients with advanced non-small cell lung cancer (NSCLC) eligible for frontline immunotherapy using biomarker test results
  • Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC

Activity Description

This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.

Faculty

Maria E. Arcila, MD
Deputy Chief, Molecular Diagnostics Service
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY


Jared M. Weiss, MD
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, NC



Content Reviewer

Jason M. Chang, MD
Assistant Attending, Molecular and Thoracic Pathology
Memorial Sloan Kettering Cancer Center
New York, NY


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Maria E. Arcila, MD, has relevant financial relationships with AstraZeneca, Bristol-Myers Squibb, Invivoscribe, Janssen Global Services, Merck, Roche (Consultant); Biocartis, Invivoscribe (Speaker/Speaker’s Bureau).

Jason M. Chang, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Jared M. Weiss, MD, has relevant financial relationships with Achilles, En Fuego (convertible note), Lyell, Nuvalent, Vesselon (warrants) (Stock/Shareholder); AbbVie, AstraZeneca, Azitra, Blueprint, Boehringer Ingelheim, Eli Lilly, EMD Serono, G1, Genentech, Genmab, Jazz Pharmaceuticals, Jounce, Nanobiotix, Pfizer, Regeneron, Saatchi, Sumitomo Dainippon Pharma Oncology (Consultant); Amgen, AstraZeneca, Boehringer Ingelheim, G1, Immunicum, Loxo/Lilly, Merck, Mirati, PDS Biotech, Sumitomo Dainippon Pharma Oncology (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 83% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: A Newly Admitted Patient With COVID-19 and Worsening Respiratory Symptoms

Case Conundrums in COVID-19: A Newly Admitted Patient With COVID-19 and Worsening Respiratory Symptoms

Start
Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: A Patient With COVID-19 Experiencing Hyperinflammation

Case Conundrums in COVID-19: A Patient With COVID-19 Experiencing Hyperinflammation

Start
Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: Primer on the Immune Basis of COVID-19 Progression

Case Conundrums in COVID-19: Primer on the Immune Basis of COVID-19 Progression

Start
Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19

Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
0.5 CME / MOC / CNE / IPCE
RMEI Medical Education, LLC
Managing Severe COVID-19 in the Hospital Setting: An Interprofessional Approach

Managing Severe COVID-19 in the Hospital Setting: An Interprofessional Approach

Start

Activity Details

Free CME/CNE/IPCE/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC Contact Hour(s)
0.5 IPCE Credit(s)™
0.5 ABIM MOC Point(s)
Released: February 11, 2022
Expires: February 10, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Assess disease severity and implications in patients with COVID-19
  • Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19
  • Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

“I was dying … and I was dying alone,” says Nancy, recalling her lonely isolation in the intensive care unit as one of the earlier victims of COVID-19 in her region. This dynamic panel features an interprofessional lineup of experts who will debate and discuss data, guidelines, and literature on the treatment of severe COVID-19 in the hospital setting and what it all means for your practice and patients. Additionally, they are joined by Nancy who survived the earliest days of COVID-19 in the United States and will share her learning moments with the panel and learners.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA

Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX


Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI,
has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.


Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 75% or higher on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE/IPCE/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC Contact Hour(s)
0.5 IPCE Credit(s)™
0.5 ABIM MOC Point(s)
Released: February 11, 2022
Expires: February 10, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Assess disease severity and implications in patients with COVID-19
  • Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19
  • Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

“I was dying … and I was dying alone,” says Nancy, recalling her lonely isolation in the intensive care unit as one of the earlier victims of COVID-19 in her region. This dynamic panel features an interprofessional lineup of experts who will debate and discuss data, guidelines, and literature on the treatment of severe COVID-19 in the hospital setting and what it all means for your practice and patients. Additionally, they are joined by Nancy who survived the earliest days of COVID-19 in the United States and will share her learning moments with the panel and learners.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA

Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX


Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI,
has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.


Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 75% or higher on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Reynold A. Panettieri, Jr, MD
1.0 AANP / CME
Global Education Group
Case-in-Point™ − Cause for Alarm: New Avenues to the Management of Severe Asthma

Case-in-Point™ − Cause for Alarm: New Avenues to the Management of Severe Asthma

Start

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 AANP Contact Hour(s)
Released: January 18, 2022
Expires: January 18, 2023
60 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
  • Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
  • Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
  • Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences

Activity Description

Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.

Moderator

Reynold A. Panettieri, Jr, MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey


Faculty

Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona


Anju T. Peters, MD, MS
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.

Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.

Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.

The following planners and managers have reported no relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

Accreditation Council for Pharmacy EducationThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Instructions for Receiving Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Term of Offering

This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 AANP Contact Hour(s)
Released: January 18, 2022
Expires: January 18, 2023
60 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
  • Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
  • Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
  • Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences

Activity Description

Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.

Moderator

Reynold A. Panettieri, Jr, MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey


Faculty

Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona


Anju T. Peters, MD, MS
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.

Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.

Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.

The following planners and managers have reported no relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

Accreditation Council for Pharmacy EducationThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Instructions for Receiving Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Term of Offering

This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Pages